Primmune Therapeutics
San Diego
About Primmune Therapeutics
Primmune Therapeutics is developing small molecule, orally-administered toll-like receptor 7 (TLR7) agonists to attack tumors and potentiate adaptive cancer immunotherapies, such as checkpoint inhibitors, to improve overall response rates and treatment durability.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $48.3M
- Funding stage: Early Stage Venture
- Last round: Series A (Nov 2021)
- Website: primmunerx.com
Industries & Categories
Biotechnology, Health Care
Social Profiles
Canonical: https://fsome.com/organization/primmune-therapeutics-40270 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.